The Complete Guide to CD19 CAR-T Technology

1
The Complete Guide to CD19 CAR-T Technology
www.creative-biolabs.com/car-t
2
Basci Introduction
A
Related Studies
B
Anti-CD19 CAR-T Cell Therapies
C
3
P
1
art
Basci Introduction
4
01
Basci Introduction
As one of the most effective treatments for
malignant tumors, CAR T refers to chimeric
antigen receptor T cell. Similar to other
immunotherapies, its basic principle is to use
the patient's own immune cells to clear the
cancer cells. But the difference is that this is
a cell therapy, not a drug. B-lymphocyte
antigen CD19, also known as CD19 molecule
(Cluster of Differentiation 19), B-Lymphocyte
Surface Antigen B4, T-Cell Surface Antigen Leu-12
and CVID3 is a transmembrane protein that in
humans is encoded by the gene CD19. It is a B
cell surface protein expressed throughout B cell
development and is expressed on nearly all B cell
malignancies including acute lymphoblastic
leukemia (ALL), chronic lymphocytic leukemia
(CLL), and many non-Hodgkin lymphoma (NHL), while
not expressed in hematopoietic stem cells. This
specificity and universal expression for a single
cell lineage make CD19 a very attractive target
for CAR-T based cell therapy. Immunologic
targeting of CD19 carries a minimal risk of bone
marrow (BM) toxicity or autoimmunity other than
the potential induction of B-cell aplasias.
5
P
2
art
Related Studies
6
(No Transcript)
7
P
3
art
Anti-CD19 CAR-T Cell Therapies
8
03
Anti-CD19 CAR-T Cell Therapies
Currently, anti-CD19 CAR-T cell therapies for
B-cell malignancies are the most advanced
engineered T cell therapies being tested.
Clinical trials in ALL and CLL have exhibited
robust and striking clinical efficacy. And, in
several reports, anti-CD19 CAR-T cell therapies
induced remissions in some patients with
considered incurable relapsed, highly refractory
ALL, refractory, bulky CLL and NHL. Despite these
positive results, Anti-CD19 CAR-T therapy still
has some risks in clinical applications, such as
high level of inflammatory cytokines and B-cell
aplasia. Tumor xenografting models involve
transplantation of tumor cells of human into
another species in order to provide in vivo
environment for therapeutic research. To date, it
is the most precise and reliable technique for
the evaluation of novel cancer therapies before
clinical trials. Typically, the construction of
an animal model requires the implantation of
tumorigenic human cell lines or human primary
tumor cells into immunocompromised mice or rats.
Tumor cells are injected subcutaneously,
intraperitoneally, or intravenously to set up
different tumor models in animals.
9
As a global company, Creative Biolabs has more
than 200 talented and well-trained scientists
located in different continents working closely
with partners from the entire world to develop
and produce medicines of tomorrow. Specifically,
we are the established leading expert in TCR and
CAR TNK cell immune therapy development, as we
offer the one-stop custom services that cover the
entire new drug development pipeline.
Additionally, we also offer an exclusive line of
ready-to-use TCR and CAR TNK cell construction
products, such as virus packaging, purification,
expansion and titer determination kits.
Furthermore, we have built up a unique
unparalleled CAR construction and production
platform for all four CAR generations.
Creative Biolabs
10
Contact Us
45-1 Ramsey Road, Shirley, NY 11967, USA
Email marketing_at_creative-biolabs.com
11
Thanks
www.creative-biolabs.com/car-t